Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 1/20 | 0.46 |
| ▸ | ABL1 | P00519 | 1/20 | 0.46 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.46 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.46 |
| ▸ | CDK7 | P50613 | 1/20 | 0.46 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.46 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.46 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.46 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.46 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.46 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 5/20 | 0.40 |
| ▸ | RAB9A | P51151 | 5/20 | 0.40 |
| ▸ | TP53 | P04637 | 7/20 | 0.37 |
| ▸ | MAPT | P10636 | 5/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13569111 | 0.78 | MAP4K4 (0.46) | MAP4K4ABL1MAPK8CSNK1A1CDK7 | |
| SCHEMBL25295742 | 0.76 | MAP4K4 (0.35) | MAP4K4ABL1MAPK8CSNK1A1CDK7 | |
| SCHEMBL14809152 | 0.74 | MAP4K4 (0.46) | MAP4K4ABL1MAPK8CSNK1A1CDK7 | |
| SCHEMBL26673743 | 0.74 | MAP4K4 (0.46) | MAP4K4ABL1MAPK8CSNK1A1CDK7 | |
| SCHEMBL434570 | 0.74 | MAP4K4 (0.54) | MAP4K4ABL1MAPK8CSNK1A1CDK7 | |
| SCHEMBL23535657 | 0.74 | NPC1 (0.46) | MAP4K4ABL1MAPK8CSNK1A1CDK7 | |
| SCHEMBL1269053 | 0.74 | MAP4K4 (0.50) | MAP4K4ABL1MAPK8CSNK1A1CDK7 | |
| SCHEMBL29278540 | 0.74 | MAP4K4 (0.46) | MAP4K4ABL1MAPK8CSNK1A1CDK7 | |
| SCHEMBL11660148 | 0.74 | MAP4K4 (0.46) | MAP4K4ABL1MAPK8CSNK1A1CDK7 | |
| SCHEMBL24798104 | 0.74 | MAP4K4 (0.63) | MAP4K4ABL1MAPK8CSNK1A1CDK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240158392-A1 | SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES | JANSSEN RESEARCH & DEVELOPMENT, LLC | 2024-05-16 | — | — | US | claimed |
| EP-4284802-A1 | SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES | Janssen Biotech, Inc. (US) | 2023-12-06 | — | — | EP | claimed |
| EP-4284801-A1 | SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES | Janssen Biotech, Inc. (US) | 2023-12-06 | — | — | EP | claimed |
| WO-2022165530-A1 | SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES | JANSSEN BIOTECH, INC. (US) | 2022-08-04 | — | — | WO | claimed |
| WO-2022165529-A1 | SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES | JANSSEN BIOTECH, INC. (US) | 2022-08-04 | — | — | WO | claimed |
| EP-3464247-A1 | NOVEL OXIDATION BASE DERIVED FROM 1-HEXYL-4,5- DIAMINOPYRAZOLE, COMPOSITION CONTAINING SAME AND USE THEREOF IN OXIDATION DYEING OF KERATIN FIBRES | L'Oréal (FR) | 2019-04-10 | — | — | EP | claimed |
| WO-2017202884-A1 | NOVEL OXIDATION BASE DERIVED FROM 1-HEXYL-4,5- DIAMINOPYRAZOLE, COMPOSITION CONTAINING SAME AND USE THEREOF IN OXIDATION DYEING OF KERATIN FIBRES | L'OREAL (FR) | 2017-11-30 | — | — | WO | claimed |
| US-12590090-B2 | Pyrimidine-and nitrogen-containing bicyclic compound | ASAHI KASEI PHARMA CORPORATION (JP) | 2026-03-31 | — | — | US | disclosed |
| US-20250066351-A1 | PYRAZOLO[1,5-A]PYRIDIN-2,3-YL AMIDES AS KV7 CHANNEL ACTIVATORS | BIOHAVEN THERAPEUTICS LTD (US) | 2025-02-27 | — | — | US | disclosed |
| CN-116194454-B | Pyrimidine-containing nitrogen-containing bicyclic compounds | 旭化成制药株式会社 | 2025-02-18 | — | — | CN | disclosed |
| EP-4460501-A1 | PYRAZOLO[1,5-A]PYRIDIN-2,3-YL AMIDES AS KV7 CHANNEL ACTIVATORS | Biohaven Therapeutics Ltd. (US) | 2024-11-13 | — | — | EP | disclosed |
| CN-118510777-A | Pyrazolo [1,5-a ] pyridin-2, 3-ylamides as Kv7 channel activators | 拜奥海芬治疗学有限公司 | 2024-08-16 | — | — | CN | disclosed |
| US-11993595-B2 | Compounds | MISSION THERAPEUTICS LIMITED (GB) | 2024-05-28 | — | — | US | disclosed |
| EP-0433854-B1 | 3-Aminopyrazolo heterocycles, their use for the determination of hydrogen peroxide, hydrogen peroxide forming systems, peroxidase, peroxidant active substances or electron rich aromatic compounds, corresponding determination process and agents | BOEHRINGER MANNHEIM GMBH (DE) | 1997-06-18 | — | — | EP | disclosed |
| US-5525480-A | USED FOR DETERMINATION OF HYDROLASES; COLORIMETRIC ANALYSIS | BOEHRINGER MANNHEIM GMBH (DE) | 1996-06-11 | — | — | US | disclosed |
| US-5457200-A | Oxidative coupling reactions for determination of hydrogen peroxide | BOEHRINGER MANNHEIM (DE) | 1995-10-10 | — | — | US | disclosed |
| US-5334505-A | For colorimetric determination of hydrolases | BOEHRINGER MANNHEIM GMBH (DE) | 1994-08-02 | — | — | US | disclosed |
| US-5234818-A | Detecting hydrogen peroxide, peroxidase by oxidative coupling with electron-rich aromatic compound | BOEHRINGER MANNHEIM GMBH (DE) | 1993-08-10 | — | — | US | disclosed |
| EP-0433854-A2 | 3-Aminopyrazolo heterocycles, their use for the determination of hydrogen peroxide, hydrogen peroxide forming systems, peroxidase, peroxidant active substances or electron rich aromatic compounds, corresponding determination process and agents | Roche Diagnostics GmbH (DE) | 1991-06-26 | — | — | EP | disclosed |
| EP-0433855-A2 | N- and O-substituted aminophenol derivatives, intermediates for their preparation, their use as hydrolase substrates, a corresponding assay and diagnostic agents | Roche Diagnostics GmbH (DE) | 1991-06-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240158392-A1 | SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES | SIK2, SIK1, SGK2 | MAP4K4 74/4885ABL1 555/4885MAPK8 239/4885 |
| US-11993595-B2 | Compounds | UCHL1, UCHL3, UCHL5 | MAP4K4 3652/4885ABL1 223/4885MAPK8 3336/4885 |
| US-20250066351-A1 | PYRAZOLO[1,5-A]PYRIDIN-2,3-YL AMIDES AS KV7 CHANNEL ACTIVATORS | KCNA7, KCNK17, KCNA1 | MAP4K4 502/4885ABL1 2844/4885MAPK8 706/4885 |
| US-12590090-B2 | Pyrimidine-and nitrogen-containing bicyclic compound | IRAK1, IRAK4, IRAK2 | MAP4K4 786/4885ABL1 639/4885MAPK8 1053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.